PubRank
Search
About
Viral Therapy in Treating Patient With Liver Cancer
Clinical Trial ID NCT01628640
PubWeight™ 35.19
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01628640
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
New viruses for cancer therapy: meeting clinical needs.
Nat Rev Microbiol
2013
1.72
2
Trial watch: Oncolytic viruses for cancer therapy.
Oncoimmunology
2013
1.36
3
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.
J Gen Virol
2012
1.34
4
Intratumoral immunization: a new paradigm for cancer therapy.
Clin Cancer Res
2014
1.24
5
Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: role of type I interferon signaling.
Virology
2012
1.12
6
Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Acta Pharmacol Sin
2015
0.92
7
Understanding and altering cell tropism of vesicular stomatitis virus.
Virus Res
2013
0.91
8
Long-distance interferon signaling within the brain blocks virus spread.
J Virol
2014
0.90
9
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.
Cancer Gene Ther
2013
0.90
10
Neuroattenuation of vesicular stomatitis virus through picornaviral internal ribosome entry sites.
J Virol
2013
0.89
11
The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
Mol Ther
2014
0.85
12
Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
J Surg Res
2013
0.84
13
Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.
J Virol
2015
0.84
14
EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA.
Drugs Future
2016
0.84
15
Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Oncotarget
2015
0.83
16
Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics.
Virology
2015
0.83
17
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data.
Hum Gene Ther
2015
0.83
18
Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.
Nat Commun
2015
0.82
19
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.
Front Oncol
2014
0.82
20
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Viruses
2015
0.80
21
Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm.
J Exp Clin Cancer Res
2014
0.80
22
How Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity?
Front Oncol
2014
0.80
23
Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma.
Front Oncol
2014
0.80
24
Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.
Virology
2015
0.79
25
Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
Gynecol Oncol
2013
0.79
26
Meningeal myeloma deposits adversely impact the therapeutic index of an oncolytic VSV.
Cancer Gene Ther
2013
0.79
27
Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck.
Head Neck
2014
0.78
28
Cellular proteins associated with the interior and exterior of vesicular stomatitis virus virions.
PLoS One
2014
0.78
29
Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
Virology
2014
0.77
30
Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"?
Mol Ther Oncolytics
2015
0.77
31
Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.
J Virol
2013
0.77
32
An unexpected inhibition of antiviral signaling by virus-encoded tumor suppressor p53 in pancreatic cancer cells.
Virology
2015
0.77
33
Signaling pathways in murine dendritic cells that regulate the response to vesicular stomatitis virus vectors that express flagellin.
J Virol
2013
0.76
34
PET imaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in a preclinical HCC rat model.
Mol Ther
2015
0.76
35
Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer.
J Virol
2015
0.75
36
Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors.
Expert Opin Orphan Drugs
2015
0.75
37
Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity.
Mol Ther Oncolytics
2015
0.75
38
Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
J Virol
2015
0.75
39
Oncolytic virotherapy for head and neck cancer: current research and future developments.
Oncolytic Virother
2015
0.75
40
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.
Mol Ther Oncolytics
2016
0.75
41
The ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implications.
Oncolytic Virother
2015
0.75
Next 100